Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).

被引：1

作者：

Capdevila, Jaume

Jimenez-Valerio, Gabriela

Martinez, Alba

Hernando, Jorge

Ibrahim, Toni

Fazio, Nicola

Lopez, Carlos

Teule, Alex

Valle, Juan W.

Tafuto, Salvatore

Custodio, Ana B.

Reed, Nicholas Simon

Raderer, Markus

Grande, Enrique

Garcia-Carbonero, Rocio

Jimenez-Fonseca, Paula

Alonso, Vicente

Casanovas, Oriol

机构：

[1] Vall dHebron Univ Hosp HUVH, Med Oncol, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[2] IDIBELL, Catalan Inst Oncology, Barcelona, Spain

[3] Inst Catala Oncol Hosp, Barcelona, Spain

[4] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Bracelona, Spain

[5] IRCCS, Osteoncol & Rare Tumors Ctr, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[6] IRCCS, European Inst Oncol, Milan, Italy

[7] Marques de Valdecilla Univ Hosp, Santander, Spain

[8] Inst Catala Oncol, Barcelona, Spain

[9] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England

[10] Ist Nazl Tumori Fdn G Pascale, Naples, Italy

[11] Hosp Univ La Paz, Madrid, Spain

[12] Gartnavel Royal Hosp, Med Oncol, Glasgow, Lanark, Scotland

[13] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria

[14] MD Anderson Canc Ctr Madrid, Madrid, Spain

[15] UCM, CNIO, Imas12, Hosp Univ 12 Octubre, Madrid, Spain

[16] Hosp Univ Cent Asturias, Oviedo, Spain

[17] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4113

引用

页数：2